Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 28, 2014; 20(24): 7602-7621
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7602
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7602
Figure 1 Algorithm for the management of incurable asymptomatic (or minimally symptomatic) stage IV colorectal cancer patients.
1Depending on the regimen previously administered. KRAS-WT: KRAS-wild type; KRAS-MT: KRAS-mutation; FOLFOX: 5-Fluorouracil + Oxaliplatin; FOLFIRI: 5-Fluorouracil + Irinotecan; NRAS-WT = NRAS-wild type; CRC: Colorectal cancer; CHT: Chemotherapy.
Figure 2 Algorithm for the management of severely symptomatic incurable stage IV colorectal cancer patients (including emergency cases).
Figure 3 Improvement of survival after various chemotherapic regimens for incurable stade IV colorectal cancer patients through the last three decades.
BSC: Best supportive care; 5-FU: 5-Fluorouracil; FOLFIRI: 5-Fluorouracil + Irinotecan; FOLFOX: 5-Fluorouracil + Oxaliplatin; IFL: 5-Fluorouracil bolus; CAPEOX: Capecitabine + Oxaliplatin; FA: Folic acid (Leucovorin); OS: Overall survival.
- Citation: Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621
- URL: https://www.wjgnet.com/1007-9327/full/v20/i24/7602.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i24.7602